Previous studies have demonstrated that EGCG directly binds to TRAF6, inhibiting the binding of E3 to Ubc13 and consequently reducing the E3 ligase activity of TRAF6, leading to a weakening of tumor malignancy. The gene discussed is UBE2N; the disease is neoplasm.